Carregant...
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Adoptive immunotherapy with T cells genetically modified to express chimeric antigen receptors (CARs) is a promising approach to improve outcomes for cancer patients. While CAR T cell therapy is effective for hematological malignancies, there is a need to improve the efficacy of this therapeutic app...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8220823/ https://ncbi.nlm.nih.gov/pubmed/34177932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.684642 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|